Clinical Trials Sponsored by Laboratoires Techni Pharma

Total 121 results

Laboratoires Techni Pharma

Completed

Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia (EDUCDYS)

Dyschesia

France
Laboratoires Techni Pharma

Completed

Efficacy of Eductyl® Versus Placebo for Treatment of Dyschesia (Eductyl)

Dyschesia

France
Laboratoires Thea
Iris Pharma

Completed

Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

Dry Eye

United Kingdom
Laboratoires Gilbert
Slb Pharma

Completed

Evaluation of the Safety and Performance of LiNiDERM® in the Prevention of Infant Diaper Rash

Diaper Rash

Poland
Laboratories Leon Farma, S.A.
Chemo France

Completed

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Contraception

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Low Back Pain

Austria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
Tris Pharma, Inc.
Forest Laboratories

Completed

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Prolonged QTc Interval | Pharmacokinetic

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

Pain | Diabetic Neuropathies

Bulgaria, Germany, Romania
Tris Pharma, Inc.
Forest Laboratories

Completed

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

Osteoarthritis of the Knee

Austria, Poland, Spain
Tris Pharma, Inc.
Forest Laboratories

Completed

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

United States
Tris Pharma, Inc.
Forest Laboratories

Completed

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Pharmacokinetic

United States
Assistance Publique - Hôpitaux de Paris
Laboratoires Vivacy; INTERmedic; Laboratoires IPRAD PHARMA

Recruiting

Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment (EPIONE-01)

Breast Cancer

France
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Rafa Laboratories
Dr. Falk Pharma GmbH

Completed

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

Graft Vs Host Disease

Israel
Laboratoire de la Mer
Slb Pharma

Not yet recruiting

PMCF to Assess Real-life Usage Effectiveness, Safety and Patient Satisfaction of a Range of Hypertonic Seawater-based Decongestant Nasal Sprays

Allergic Rhinitis | URTI
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Laboratoires Thea
Iris Pharma; Axial Biotech, Inc

Completed

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice (MEIBUM)

Meibomian Gland Dysfunction | Ocular Surface Disease | Palpebral Pathologies

Germany, Spain
UCB Korea Co., Ltd.
Seoul Pharma Laboratories Inc.

Completed

Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects

Healthy

Korea, Republic of
PT Harsen Laboratories
PT Pharma Metric Labs

Completed

Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

Drug Use

Indonesia
Brillian Pharma Inc.
Accutest Research Laboratories (I) Pvt. Ltd.

Completed

Amlodipine Freeze-Dried Powder for Oral Solution 5 mg

Coronary Artery Disease | Hypertension

India
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories...
Attikon Hospital

Terminated

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)

Covid-19 | Pulmonary Infection

Greece
InnoCare Pharma Inc.
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluating Different Doses of Orelabrutinib in MCL

Mantle Cell Lymphoma

China
GL Pharm Tech Corporation

Unknown

Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

Dry Eye Syndromes

Korea, Republic of
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects (GLA5PR-101)

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers (GL2907-101)

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

Dry Eye Syndromes

Korea, Republic of
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

Healthy
GL Pharm Tech Corporation

Completed

PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects (GLA5PR-102)

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Unknown

The Pharmacokinetics of GLA5PR Tablet According to the Renal Function

Neuropathic Pain

Korea, Republic of
GL Pharm Tech Corporation

Completed

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS (GL2702)

Benign Prostatic Hyperplasia

Korea, Republic of
GL Pharm Tech Corporation

Completed

A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

Healthy
Risen (Suzhou) Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China

3

Subscribe